CytoDyn has spent the past two years under siege – from the FDA, disgruntled investors and by association, the U.S. Department of Justice. Now, the company’s leadership hopes to chart a new future in non-alcoholic fatty liver disease.
Tag Archive for: non-alcoholic fatty liver disease
The positive data sets the stage for the drug, resmetirom, to become the first approved treatment for NASH, or nonalcoholic steatohepatitis, a disease that affects about 5% of adults in the United States.
On Thursday, Pfizer announced the U.S. Food and Drug Administration granted the company’s combinatorial therapeutic ervogastat/clesacostat Fast Track Designation. The therapeutic combo is intended for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.
